NASDAQ · MIRM
Healthcare · Biotechnology
$79.25
Down-$2.18 (-2.68%)
Updated Oct 7, 2026, 6:04 AM
SID Score
4.1/10
Composite research score
Smart Money
58/100
Neutral
Price performance · MIRM
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
MIRM closed at $79.25 after 21 trading sessions, down 20.38% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $81.94 | $81.94 | $77.78 | $79.25 | 1.15M |
| Oct 5, 2026 | $83.30 | $83.35 | $81.23 | $81.43 | 980.14K |
| Oct 2, 2026 | $84.67 | $84.68 | $81.41 | $82.93 | 1.13M |
| Oct 1, 2026 | $85.42 | $86.17 | $83.6825 | $83.92 | 641.94K |
| Sep 30, 2026 | $88.85 | $88.85 | $85.36 | $85.48 | 901.73K |
| Sep 29, 2026 | $89.04 | $90.31 | $86.51 | $87.54 | 666.83K |
| Sep 28, 2026 | $90.00 | $91.2499 | $84.71 | $87.96 | 1.24M |
| Sep 25, 2026 | $89.90 | $90.81 | $88.275 | $89.70 | 765.8K |
| Sep 24, 2026 | $89.24 | $90.69 | $87.635 | $89.36 | 681.43K |
| Sep 23, 2026 | $91.31 | $91.50 | $87.87 | $89.32 | 739.15K |
| Sep 22, 2026 | $92.49 | $92.82 | $90.55 | $91.39 | 775.17K |
| Sep 21, 2026 | $93.07 | $94.57 | $91.04 | $92.00 | 685.08K |
| Sep 18, 2026 | $98.76 | $98.76 | $91.73 | $91.83 | 1.8M |
| Sep 17, 2026 | $99.53 | $100.50 | $97.255 | $98.82 | 937.61K |
| Sep 16, 2026 | $93.95 | $98.83 | $93.76 | $97.37 | 991.19K |
| Sep 15, 2026 | $97.57 | $97.57 | $93.57 | $93.90 | 948.71K |
| Sep 14, 2026 | $98.37 | $100.00 | $96.54 | $96.75 | 488.54K |
| Sep 11, 2026 | $102.78 | $103.275 | $97.80 | $98.22 | 441.1K |
| Sep 10, 2026 | $98.30 | $101.1799 | $97.48 | $100.61 | 587.04K |
| Sep 9, 2026 | $98.02 | $101.50 | $97.01 | $98.30 | 521.76K |
| Sep 8, 2026 | $98.49 | $101.8275 | $97.645 | $99.53 | 638.47K |
The latest Smart Investors Daily articles mentioning MIRM.
Company
Market Activity
Research & News
MIRM research
Company profile and research snapshot.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | Citigroup | Buy | — |
| Sep 29, 2026 | Baird | Outperform | — |
| Sep 28, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 27, 2026 | Citizens | Market Outperform | — |
| Aug 6, 2026 | Citizens | Market Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 2, 2026
Mirum Pharmaceuticals (NASDAQ:MIRM) reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational antibody met its primary endpoint at 24 weeks and showed a favorable tolerability profile. The company
Yahoo · Sep 30, 2026
A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.
Benzinga · Sep 29, 2026
Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $145 to $160.
Yahoo · Sep 29, 2026
MIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MIRM.
